Table 2.
DIAN and PREVENT-AD test set characteristics.
| DIAN mutation non-carriers | DIAN mutation carriers | PREVENT-AD | |
|---|---|---|---|
| N | 29 | 125 | 256 |
| Chronological Age (years; mean ± SD) | 38.90 (±11.55) | 34.33 (±9.66) | 63.51 (±5.37) |
| Sex Ratio F/M (%) | 18/11 (62%/38%) | 68/57 (54%/46%) | 189/67 (74%/26%) |
| Education (years; mean ± SD) | 14.41 (2.13) | 14.89 (±3.10) | 15.65 (±3.51) |
| EYO (years; mean ± SD)a | −8.56 (±10.85) | −14.18 (±8.94) | −10.42 (±7.21) |
| APOE4 carriers (%)b | 11 (38%) | 36 (29%) | 108 (42%) |
| Aβ-positive (%)c | 0 (0%) | 39 (34%) | 14 (22%) |
| MMSE or MoCA (mean ± SD)d | 29.36 ± 1.03 | 29.02 ± 1.27 | 28.11 ± 1.52 |
Aβ beta-amyloid, Aβ− amyloid-negative, Aβ+ amyloid-positive; APOE apolipoprotein E, EYO Estimated Years to Symptom Onset, MMSE Mini–Mental State Examination, MoCA Montreal Cognitive Assessment, SD standard deviation.
aEYO in DIAN was calculated based on the parental age at onset. EYO of PREVENT-AD was calculated only for individuals with a parental history of AD, data was available for 241 participants.
bAPOE genotyping was missing for 1 PREVENT-AD participant.
cAβ-PET data was missing for 2 mutation non-carriers and 11 mutation carriers in DIAN and 192 PREVENT-AD participants.
dGlobal cognitive functioning was assessed using MMSE in DIAN and MoCA in PREVENT-AD.